Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
JPM Day 2: Obesity’s Volume vs. Value Moment Day 2 of the J.P. Morgan Healthcare Conference crystallized two themes that will define biopharma strategy for
JPM Day 1 Recap: The 44th Annual J.P. Morgan Healthcare Conference opened in San Francisco yesterday with investor attention focused decisively on launch execution rather
The J.P. Morgan Healthcare Conference has always been part deal-making, part theater. But the 2026 edition opened with something different: real price discovery. Eli Lilly
$2.2 Billion in One Day: What January 8, 2026 Reveals About Biotech’s Next Chapter On a single Thursday in January, nearly $2.2 billion moved through
The “risk-on” signal evolved into institutional flood Wednesday as XBI exploded +3.6% closing $126.43 driven by massive secondary offering demand signaling capital strike officially over
The “risk-on” switch flipped 5 days before J.P. Morgan Healthcare Conference as XBI surged +1.6% closing $122.09 with biotech outperforming S&P 500 driven by perfect
The “quiet period” officially ends 6 days before J.P. Morgan Healthcare Conference as Sanofi (SNY) acquires Dynavax (DVAX) for $15.50/share ($2.2B all-cash) securing Heplisav-B hepatitis
The JPM 2026 Planner: Shadow Week Playbook & 5 Stocks to Buy Before Conference Editor’s Note: This post has been updated to reflect corrected data.
CORRECTION: This article has been updated to reflect accurate regulatory outcomes. Original version incorrectly stated Corcept approval and Omeros CRL due to data processing error
Monday validation rally delivered XBI +1.8% breakout to $106.12 confirming market endorsement of weekend’s transformative catalysts as policy clarity (TrumpRx 3-year tariff exemption) outweighs pricing
